BDX vs REPL
Becton Dickinson and Company (BDX) versus Replimune Group Inc (REPL) — a side-by-side from cached financials, not a winner call.
Becton Dickinson and Company (BDX) is a medical instruments & supplies company listed on US.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
Latest reported BDX revenue for 2025-09-30 was $21.84B. Net income was $1.68B. Revenue was up 8.2% from 2024-09-30 to 2025-09-30. BDX currently screens at market cap $50.30B and trailing P/E 33.9.
REPL does not have a complete income-statement cache yet.
BDX currently screens at market cap $50.30B and trailing P/E 33.9. REPL currently screens at market cap $825.7M.
Not investment advice. Open the BDX and REPL stock pages for the full models.
Not investment advice.